Advertisement

Search Results

Advertisement



Your search for The ASCO Post matches 203 pages

Showing 1 - 50


gynecologic cancers

Al Identifies Features of Tumor Cells in High-Risk Ovarian Cancer  

Scientists have developed a new test that scans the shapes of tumor cells to select women with especially aggressive ovarian cancer. A team at The Institute of Cancer Research (ICR), London, created an artificial intelligence (AI) tool that looks for clusters of cells within tumors with misshapen...

breast cancer
gynecologic cancers
issues in oncology

BRCA Exchange: Resource Aggregates Data on BRCA Variants

A global resource that includes data on thousands of inherited variants in the BRCA1 and BRCA2 genes is available to the public. The BRCA Exchange was created through the BRCA Challenge, a long-term demonstration project initiated by the Global Alliance for Genomics and...

gynecologic cancers

FDA Approves Olaparib for Maintenance Treatment of BRCA-Mutated, Advanced Ovarian Cancer

On December 19, 2018, the U.S. Food and Drug Administration (FDA) approved olaparib (Lynparza) for the maintenance treatment of adult patients with deleterious or suspected deleterious germline or somatic BRCA-mutated advanced epithelial ovarian, fallopian tube, or primary peritoneal cancer...

colorectal cancer
gynecologic cancers

CIMRA Assay for Detection of Gene Variants in Lynch Syndrome

An international team of researchers has developed, calibrated, and validated a novel tool for identifying the genetic changes in Lynch syndrome genes that are likely to be responsible for causing symptoms of the disease. The results were published by Drost et al in Genetics in Medicine. ...

breast cancer
gynecologic cancers
lymphoma
pancreatic cancer
gastroesophageal cancer
bladder cancer
symptom management
gastrointestinal cancer

FDA Pipeline: What’s New in Biosimilars, Drug Reviews, Designations, and More

The U.S. Food and Drug Administration (FDA) recently issued the following new approvals and designations: Approval for Pegfilgrastim Biosimilar The FDA recently approved a pegfilgrastim biosimilar, pegfilgrastim-cbqv (Udenyca). The biosimilar has been approved to decrease the incidence...

gynecologic cancers

ESMO 2018: SOLO-1: Olaparib Maintenance Extends Progression-Free Survival in BRCA1/2-Mutated Advanced Ovarian Cancer

Two-year maintenance therapy with olaparib (Lynparza), a poly ADP-ribose polymerase (PARP) inhibitor, led to a substantial improvement in progression-free survival (PFS) in newly diagnosed patients with advanced ovarian cancer and a BRCA1/2 mutation, results from the phase III SOLO-1 trial...

gynecologic cancers

FDA Approves Expanded Use of Gardasil 9 to Include Individuals Aged 27 to 45

The U.S. Food and Drug Administration (FDA) has approved a supplemental application for recombinant human papillomavirus (HPV) 9-valent vaccine (Gardasil 9), expanding the approved use of the vaccine to include women and men aged 27 through 45 years. Gardasil 9 prevents certain cancers and...

gynecologic cancers
immunotherapy

Addition of a CTLA-4–Targeted Therapy to a Checkpoint Inhibitor in Ovarian Cancer

An analysis of the NRG Oncology clinical trial NRG-GY003 suggests that adding ipilimumab (Yervoy), a monoclonal antibody that targets the protein receptor cytotoxic T-lymphocyte–associated protein 4 (CTLA-4), to a regimen with the checkpoint inhibitor nivolumab (Opdivo) could improve response ...

gynecologic cancers
head and neck cancer
issues in oncology

HPV Vaccine Completion Up 5% From 2016 to 2017

The number of adolescents who are up to date on human papillomavirus (HPV) vaccination—meaning they started and completed the HPV vaccine series—increased 5 percentage points from 2016 to 2017, according to results from a national survey published by Walker et al in Morbidity and...

gynecologic cancers

FDA Grants Fast Track Designation to AVB-S6-500 for Platinum-Resistant Ovarian Cancer

The U.S. Food and Drug Administration (FDA) has granted Fast Track designation to AVB-S6-500 as a potential treatment for platinum-resistant recurrent ovarian cancer. About AVB-S6-500 AVB-S6-500 is a novel high-affinity, soluble Fc-fusion protein designed to block the activation of the GAS6-AXL...

breast cancer
gynecologic cancers
issues in oncology

BRCA Testing in Medically Underserved Women in Southeastern United States

Medically underserved women in the Southeast region of the United States diagnosed with breast cancer or ovarian cancer may have not received genetic testing that could have helped them and their relatives make important decisions about their health, according to new research from Vanderbilt-Ingram ...

gynecologic cancers
pancreatic cancer

FDA Grants Breakthrough Device Designation for Cancer Detection Liquid Biopsy

PapGene, Inc, has announced their cancer detection test has received Breakthrough Device designation from the Center for Devices and Radiological Health (CDRH) of the U.S. Food and Drug Administration (FDA). The PapGene test is a multianalyte test that uses a combination of circulating tumor DNA...

gynecologic cancers

careHPV Test Receives WHO Prequalification Status for Cervical Cancer Screening

The careHPV Test, a molecular diagnostic for high-risk human papillomavirus (HPV) designed to screen women in low-resource settings, has been added to the World Health Organization (WHO) list of prequalified in vitro diagnostics (IVDs). HPV is the primary cause of cervical cancer, so ...

gynecologic cancers
immunotherapy

FDA Grants Breakthrough Therapy Designation to Lenvatinib Plus Pembrolizumab in Endometrial Carcinoma

The U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy designation for lenvatinib (Lenvima) in combination with pembrolizumab (Keytruda) for the potential treatment of patients with advanced and/or metastatic non–microsatellite instability high (MSI-H)/proficient...

gynecologic cancers
health-care policy

Study Evaluates Effects of Affordable Care Act on Young Women With Gynecologic Cancer

The gains in insurance coverage with the Patient Protection and Affordable Care Act (ACA) have already translated into improved health for young women with gynecologic cancers, who are getting diagnosed at earlier stages of their disease because of ACA benefits. That’s the conclusion of a new ...

gynecologic cancers
issues in oncology

ESHRE 2018: Large Population Study Does Not Find Causal Link Between Assisted Reproduction and Ovarian Cancer Risk

Following concerns over many years that hormonal stimulation of the ovaries necessary for in vitro fertilization (IVF) may increase the risk of ovarian cancer, a nationwide cohort study from Denmark has now concluded that any perceived increase in risk is actually a statistical bias resulting from...

gynecologic cancers

FDA Grants Priority Review to Expanded Use of Gardasil 9 in Women and Men Aged 27 to 45 for the Prevention of Certain HPV-Related Cancers and Diseases

On June 13, the U.S. Food and Drug Administration (FDA) accepted for review a new supplemental biologics license application (sBLA) for recombinant human papillomavirus (HPV) 9-valent vaccine (Gardasil  9). The application is seeking approval for an expanded age...

gynecologic cancers
immunotherapy

FDA Approves Bevacizumab Plus Chemotherapy in Advanced Ovarian Cancer Following Initial Surgery

Today, the U.S. Food and Drug Administration (FDA) approved bevacizumab (Avastin) in combination with chemotherapy (carboplatin and paclitaxel) followed by bevacizumab as a single agent for the treatment of women with advanced (stage III or IV) ovarian cancer following initial surgical resection....

gynecologic cancers
immunotherapy

FDA Approves Pembrolizumab for Previously Treated Recurrent or Metastatic PD-L1–Expressing Cervical Cancer

On June 12, the U.S. Food and Drug Administration (FDA) approved pembrolizumab (Keytruda) for the treatment of patients with recurrent or metastatic cervical cancer and disease progression on or after chemotherapy whose tumors express programmed cell death ligand 1 (PD-L1) [Combined Positive Score...

colorectal cancer
solid tumors
gynecologic cancers

2018 ASCO: Genomic Study Finds Lynch Syndrome Is Common Among Patients With MSI-High Tumors

A genomic study of more than 15,000 tumor samples showed that people who have tumors with high microsatellite instability (MSI-H)—a genomic marker associated with a large number of genetic mutations in the tumor—are more likely to have Lynch syndrome, a hereditary condition that...

gynecologic cancers

Positive Results From QUADRA Trial of Niraparib in Ovarian Cancer

Tesaro recently announced results from the QUADRA study, which was designed to assess the clinical benefit of niraparib (Zejula) treatment in heavily pretreated patients with ovarian cancer. Results successfully achieved the prespecified primary endpoint and demonstrated niraparib monotherapy...

gynecologic cancers

ESTRO 37: Brachytherapy for Patients With Cervical Cancer Does Not Increase Risk of Ureteral Stricture

A rare but potentially serious complication following radiation treatment for cervical cancer is a narrowing of the tube that takes urine from the kidneys to the bladder (the ureter), which can lead to kidney damage and sometimes life-threatening infections. This is called ureteral stricture and,...

gynecologic cancers
immunotherapy

Personalized Tumor Vaccine Shows Promise in Advanced Ovarian Cancer

A new type of cancer vaccine has yielded promising results in an initial clinical trial conducted at the Perelman School of Medicine at the University of Pennsylvania and the Abramson Cancer Center of the University of Pennsylvania. The personalized vaccine is made from a patient’s own immune ...

gynecologic cancers

FDA Expands Rucaparib Approval to Include Maintenance Treatment of Recurrent Ovarian Cancer

Today, the U.S. Food and Drug Administration (FDA) approved rucaparib (Rubraca) tablets for the maintenance treatment of adult patients with recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer who have a complete or partial response to platinum-based chemotherapy. The FDA...

gynecologic cancers

SGO 2018: Participation in Clinical Trials May Overcome Health Disparities in Ovarian Cancer

Participation in clinical trials may overcome health disparities in the treatment of advanced or recurrent ovarian cancer, according to a study presented at the Society of Gynecologic Oncology’s (SGO) 2018 Annual Meeting on Women’s Cancer (Abstract 6). The study evaluated the effect of ...

gynecologic cancers
immunotherapy

SGO 2018: Immunotherapy/PARP Inhibitor Combination Produces Remissions in Ovarian Cancer

A combination of the immunotherapy pembrolizumab (Keytruda) and the DNA repair–blocking agent niraparib (Zejula) can be significantly more effective than either drug alone in women with hard-to-treat ovarian cancer, a phase I/II clinical trial led by Dana-Farber Cancer Institute researchers...

gynecologic cancers

SGO 2018: New Data Suggest Cervical Cancer Age-Based Screening Guidelines Should Be Reconsidered

One in five women diagnosed with cervical cancer in the United States will be diagnosed after the age of 65, suggesting that the recommended age to stop cervical cancer screening should be reconsidered, according to research presented at the Society of Gynecologic Oncology’s (SGO) 2018 Annual ...

gynecologic cancers

SGO 2018: Gender Differences May Play a Role in Lack of HPV Vaccination

Parents are less likely to vaccinate adolescent boys than girls with the human papillomavirus (HPV) vaccine, and they are twice as likely to report their main reason as a lack of provider recommendation, according to a study presented at the 2018 Society of Gynecologic Oncology (SGO) Annual Meeting ...

gynecologic cancers

SGO 2018: PARP-7 Protein May Play a Significant Role in Survival for Ovarian Cancer

Patients with ovarian cancer with genetic amplification in the PARP-7 protein survived longer than those without the mutation, according to a presentation at the Society of Gynecologic Oncology’s (SGO) 2018 Annual Meeting on Women’s Cancer. These results call for researchers to further...

gynecologic cancers

AACR 2018: Chlamydia Infection May Be Associated With Increased Risk of Ovarian Cancer

An antibody that is present in the blood of women previously infected with the sexually transmitted infection chlamydia is associated with a doubling in ovarian cancer risk, according to data presented during a media preview for the 2018 American Association for Cancer Research (AACR) Annual...

gynecologic cancers
immunotherapy

FDA Accepts Pembrolizumab sBLA for Treatment of Advanced Cervical Cancer

On March 13, Merck announced that the U.S. Food and Drug Administration (FDA) has accepted a new supplemental biologics license application (sBLA) and granted Priority Review for pembrolizumab (Keytruda), the company’s anti–programmed cell death protein 1 (PD-1) therapy. The application ...

gynecologic cancers

Multitargeted Tyrosine Kinase Inhibitor Shows Activity in Small Cell Carcinoma of the Ovary

An multitargeted tyrosine kinase inhibitor used to treat leukemia has shown promise against a rare and aggressive type of ovarian cancer—small cell carcinoma of the ovary hypercalcemic type (SCCOHT)—that strikes young women and girls, according to a study led by the Translational...

gynecologic cancers

FDA Grants Premarket Approval to New HPV Assay

On February 14, Becton, Dickinson and Company (BD) announced it had received premarket approval from the U.S. Food and Drug Administration (FDA) for the BD Onclarity human papillomavirus (HPV) assay. The test detects 14 types of high-risk HPV from specimens collected for cervical cancer screening...

breast cancer
colorectal cancer
gynecologic cancers
hepatobiliary cancer
lung cancer
pancreatic cancer
gastroesophageal cancer

Detecting and Localizing Eight Cancer Types With One Multianalyte Blood Test

Johns Hopkins Kimmel Cancer Center researchers developed a single blood test that screens for eight common cancer types and also helps identify the location of the cancer. The test, called CancerSEEK, is a unique noninvasive, multianalyte test that simultaneously evaluates levels of eight cancer...

gynecologic cancers

FDA Accepts sNDA for Rucaparib in Recurrent Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

On December 5, Clovis Oncology announced that the U.S. Food and Drug Administration (FDA) has accepted a supplemental New Drug Application (sNDA) for rucaparib (Rubraca) and granted Priority Review status to the application, with a Prescription Drug User Fee Act (PDUFA) date of April 6, 2018. In...

gynecologic cancers

FDA Accepts sBLA for Bevacizumab as a Front-Line Treatment for Advanced Ovarian Cancer

On October 25, Genentech announced that the U.S. Food and Drug Administration (FDA) has accepted the company's supplemental Biologics License Application (sBLA) for bevacizumab (Avastin) in combination with chemotherapy (carboplatin and paclitaxel), followed by bevacizumab alone, for the front-line ...

gynecologic cancers

sNDA Submitted for Rucaparib as Maintenace Treatment for Patients With Platinum-Sensitive Recurrent Ovarian Cancer

On October 9, Clovis Oncology announced that the company submitted a supplemental New Drug Application (sNDA) to the U.S. Food and Drug Administration for rucaparib (Rubraca) as maintenance treatment of patients with recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer...

gynecologic cancers

Role of the E7 Gene in High-Risk HPV

National Cancer Institute (NCI) researchers have found that for the most common high-risk type of human papillomavirus (HPV) to cause cervical cancer, an important viral gene may need to have a precise DNA sequence. The findings, published by Mirabello et al in Cell, contribute to a better...

gynecologic cancers

ASTRO 2017: GOG-249 Confirms Adjuvant Pelvic Radiation as Standard of Care for High-Risk, Early-Stage Endometrial Cancer

In a new phase III trial report from the National Clinical Trial Network group, NRG Oncology, recurrence-free and overall survival rates for women with stage I–II high-risk endometrial cancer were not superior following adjuvant vaginal cuff brachytherapy plus chemotherapy when compared with...

gynecologic cancers

ASTRO 2017: IAEA Trial: Safety, Efficacy of High-Dose Brachytherapy Plus Pelvic Radiation for Cervical Cancer

Findings from a new multicenter, international clinical trial confirm the effectiveness of high-dose brachytherapy, or internal radiation therapy, for managing locally advanced cervical cancer. Tumor control was significantly better following four fractions of 7 Gy each than following two 9-Gy...

gynecologic cancers

Olaparib Receives Positive pCODR Recommendation for Treatment of BRCA-Mutated Ovarian Cancer

The pan-Canadian Oncology Drug Review (pCODR) has provided a positive clinical recommendation for the reimbursement of olaparib (Lynparza), a first-of-its-kind treatment for BRCA-mutated ovarian cancer. Lynparza is an oral, potent inhibitor of poly (ADP-ribose) polymerase (PARP) available as a...

cns cancers
gynecologic cancers
kidney cancer
lung cancer
gastroesophageal cancer

FDA Approves First Biosimilar for the Treatment of Cancer

The U.S. Food and Drug Administration today approved bevacizumab-awwb (Mvasi) as a biosimilar to bevacizumab (Avastin) for the treatment of multiple types of cancer. Bevacizumab-awwb is the first biosimilar approved in the U.S. for the treatment of cancer. “Bringing new biosimilars to...

gynecologic cancers

ESMO 2017: Study Confirms Chemoradiation Is Best Treatment for Locally Advanced Cervical Cancer

A 14-year randomized trial in more than 600 patients has concluded that chemoradiation should remain the standard treatment for patients with locally advanced cervical cancer. The findings were reported at the European Society for Medical Oncology (ESMO) 2017 Congress in Madrid (Abstract 928O_PR). ...

gynecologic cancers

ESMO 2017: Rucaparib Boosts Progression-Free Survival in BRCA-Mutant Recurrent Ovarian Cancer

Rucaparib (Rubraca) maintenance therapy increases progression-free survival in BRCA-mutant recurrent ovarian cancer by 77%, according to late-breaking results from the ARIEL3 trial reported at the European Society for Medical Oncology (ESMO) 2017 Congress in Madrid (Abstract LBA40_PR). Most...

gynecologic cancers

ESMO 2017: ICON8 Trial Reaffirms Standard Chemotherapy Dosing in Ovarian Cancer

Caucasian women with ovarian cancer can safely stick to the standard every-3-week dosing schedule for paclitaxel rather than boosting up to a weekly dose-dense regimen, according to results of the phase III ICON8 trial presented at the European Society for Medical Oncology (ESMO) 2017 Congress in...

breast cancer
gynecologic cancers

Loss of Heterozygosity in BRCA Gene May Influence Survival in Breast and Ovarian Cancers

Researchers in the Perelman School of Medicine at the University of Pennsylvania have found a relationship between the genetics of tumors with germline BRCA1/2 mutations—and whether the tumor retains the normal copy of the BRCA1/2 gene—and risk for primary resistance to a common...

gynecologic cancers

FDA Approves Olaparib Tablets for Maintenance Treatment in Ovarian Cancer

On August 17, 2017, the U.S. Food and Drug Administration (FDA) granted regular approval to olaparib tablets (Lynparza) for the maintenance treatment of adult patients with recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer, who are in a complete or partial response to...

gynecologic cancers

Increased Endometrial Cancer Rates Found in Women With Increased Levels of Cadmium

Through a 5-year observational study recently published by McElory et al in PLOS One, researchers at the University of Missouri (MU) found that women with increased levels of cadmium—a metal commonly found in foods such as kidney, liver, and shellfish, as well as tobacco—had an...

gynecologic cancers

New Device to Test for Cervical Cancer May Be Less Painful for Patients, Produce Better Results

When a woman has an abnormal Papanicolaou (Pap) smear, she usually undergoes colposcopy—a procedure physicians use to closely examine the cervix, vagina, and vulva for signs of disease. Typically, a metal instrument is used to obtain a small sampling of cells inside the cervix, which is...

gynecologic cancers

ASCO 2017: HPV Vaccination May Reduce Oral HPV Infections but Is Still Underutilized

In one of the first large studies to explore the possible impact of human papillomavirus (HPV) vaccination on oral HPV infections, researchers found it may confer a high degree of protection. The study of young adults in the United States showed that the prevalence of high-risk HPV infection was...

Advertisement

Advertisement



;
Advertisement